Cardiometabolic disorders and weight: A complex constellation of interrelated conditions

Article

This constellation of conditions-cardiometabolic disorders and weight-has become one of the most pressing public health issues today, affecting approximately a quarter of the U.S. population, accounting for a substantial proportion of health-care and prescription drug spending, and threatening the vitality of an aging population.

Key Points

An estimated 47 million Americans have double the average risk of heart disease because they are affected by a complex constellation of interrelated conditions, including obesity, impaired glucose metabolism, hypertension, and lipid disorders.1 These patients also are five times more likely to develop diabetes, according to the National Heart, Lung, and Blood Institute.1

This constellation of conditions-cardiometabolic disorders and weight (CMDW)-has become one of the most pressing public health issues today, affecting approximately a quarter of the U.S. population, accounting for a substantial proportion of health-care and prescription drug spending, and threatening the vitality of an aging population.1,2

Obesity

Recent research indicates that excess visceral adipose tissue releases metabolites, cytokines, chemokines, and hormones that influence inflammation and other factors to affect atherogenesis and the vessel wall directly.6

In an effort to slow the obesity epidemic, 19 states have set stricter nutritional standards for school meals, 27 states have nutritional standards for foods sold in schools, and 20 now require body mass index screening or other weight assessment of schoolchildren.7

Impaired glucose metabolism

In the United States, 17.9 million patients have diagnosed diabetes; an estimated 5.7 million cases remain undiagnosed, and an additional 57 million people have prediabetes, according to the American Diabetes Association.8 The incidence of diabetes among those aged 60 years or more is 23.1%. An estimated 16.5% of the adult American Indian and Alaska native population are affected by diabetes.8 After adjusting for age differences, the prevalence of diabetes is 11.8% among non-Hispanic blacks, 10.4% among Hispanic Americans, 7.5% in Asian Americans, and 6.6% among non-Hispanic whites.8

Overall, approximately 210,000 Americans aged more than 20 years have diabetes, an incidence of 0.26%, but the data do not differentiate between diabetes types.8 Type 2 diabetes, however, is being diagnosed more frequently in children, especially among Native Americans and African and Hispanic Americans. In addition, one in six overweight adolescents-approximately 2 million-have prediabetes.8

Recent Videos
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, discusses keratoconus management, diagnosis, and other key insights at CRU 2025.
Cecelia Koetting, OD, FAAO, DipABO, details a talk she gave among optometrists and ophthalmologists at CRU 2025.
Alongside Rachelle Lin, OD, MS, FAAO; Nguyễn, MD, MSc, detailed what treatments are currently available for retinal vascular diseases, including neovascular age-related macular degeneration and diabetic retinopathy.
Dr Paul Karpecki discusses atropine formulation from Sydnexis following NDA acceptance by FDA
Ali Tafreshi sits down with Optometry Times to discuss Topcon's "Healthcare from the Eye" initiative.
Nora Lee Cothran, OD, FAAO, details a real-world study that found IOP-lowering benefits when switching patients with glaucoma to latanoprostene bunod treatment.
OptiLIFT in action: Dr. Julie McLaughlin's experience with the new device
© 2025 MJH Life Sciences

All rights reserved.